Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 12:42:43 GMT 2023
by
admin
on
Sat Dec 16 12:42:43 GMT 2023
|
| Protein Type | RECEPTOR |
| Protein Sub Type | GROWTH FACTOR RECEPTOR |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
Z8GA0YQ49Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
EC 2.7.10.1
Created by
admin on Sat Dec 16 12:42:43 GMT 2023 , Edited by admin on Sat Dec 16 12:42:43 GMT 2023
|
PRIMARY | |||
|
P00533
Created by
admin on Sat Dec 16 12:42:43 GMT 2023 , Edited by admin on Sat Dec 16 12:42:43 GMT 2023
|
PRIMARY | |||
|
Z8GA0YQ49Y
Created by
admin on Sat Dec 16 12:42:43 GMT 2023 , Edited by admin on Sat Dec 16 12:42:43 GMT 2023
|
PRIMARY | |||
|
T790M
Created by
admin on Sat Dec 16 12:42:43 GMT 2023 , Edited by admin on Sat Dec 16 12:42:43 GMT 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_7 | 1_34 |
| 1_133 | 1_163 |
| 1_166 | 1_175 |
| 1_170 | 1_183 |
| 1_191 | 1_199 |
| 1_195 | 1_207 |
| 1_208 | 1_216 |
| 1_212 | 1_224 |
| 1_227 | 1_236 |
| 1_240 | 1_267 |
| 1_271 | 1_283 |
| 1_287 | 1_302 |
| 1_305 | 1_309 |
| 1_313 | 1_338 |
| 1_446 | 1_475 |
| 1_482 | 1_491 |
| 1_486 | 1_499 |
| 1_502 | 1_511 |
| 1_515 | 1_531 |
| 1_534 | 1_547 |
| 1_538 | 1_555 |
| 1_558 | 1_567 |
| 1_571 | 1_593 |
| 1_596 | 1_604 |
| 1_600 | 1_612 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_32 |
| N | 1_49 |
| N | 1_104 |
| N | 1_151 |
| N | 1_172 |
| N | 1_328 |
| N | 1_337 |
| N | 1_389 |
| N | 1_420 |
| N | 1_504 |
| N | 1_544 |
| N | 1_579 |
| N | 1_599 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
Potent irreversible inhibitor of EGFR harbouring resistance (T790M) or activating (L858R and exon 19 deletions) mutations [6]. The half maximal inhibitory concentration (IC50) of furmonertinib against these mutant EGFRs is ≈ 1 nmol/L, which is lower than its IC50 against wild-type EGFR.
IC50
|
||
|
|
INHIBITOR -> TARGET |
IRREVERSIBLE INHIBITOR
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
IRREVERSIBLE INHIBITOR
|
||
|
INHIBITOR -> TARGET |
IC50
|
||
|
|
INHIBITOR -> TARGET |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER AVERAGE(CALCULATED) | CHEMICAL |
|